↓ Read PDF
01 · ABSTRACT

Abstract

Methotrexate induced pneumonitis is a rare (0.3-7.5%) (1–3) but serious and potentially fatal complication (4) of the treatment with this folic acid antagonist in patients with rheumatoid arthritis (RA) and other diseases. Typically, it begins as an acute or subacute episode of dry cough, dyspnea and fever, within the first year of treatment, more frequently during the first months (mean: 36-78 weeks) (5), and, regardless of the prescribed dose, smoking habits and gender of the patient. Other risk factors such as advanced age, extra-articular manifestations of rheumatoid arthritis (especially pulmonary involvement), diabetes and elevated creatinine level, have been identified (6). If suspected, methotrexate should be discontinued immediately and respiratory support treatment plus systemic steroids at medium-high doses should be initiated. In addition, it is recommended to associate a broad spectrum antibiotic treatment, covering Pneumocystis jirovecii (7), until the infectious origin is discarded (2). We present a 71-year-old female who presented this rare pathology three years ago, as a consequence of being treated with methotrexate (MTX) for rheumatoid arthritis diagnosed three months earlier.

↓ Read PDF
02 · OJS METADATA

Keywords

medicalmedicineresearchpharmacology
03 · PUBLICATION RECORD

Article details

JournalMedical Research Archives
IssueVol 5 No 7 (2017): Vol.5 Issue 7 - July 2017
SectionResearch Articles
Published15 July 2017
ISSN2375-1924
04 · RIGHTS & REUSE

Rights & reuse

This article is published under a Creative Commons Attribution License (CC BY 3.0) and may be shared or distributed by anyone as long as attribution is given to the journal.

Authors & affiliations

Medical Research Archives

Submit your own article

Register as an author to reserve your spot in the next issue of the Medical Research Archives.

Start your submission  ↗